Sarepta releases mixed top-line results from EMBARK study of Elevidys

31 October 2023
sarepta-big

US biotech Sarepta Therapeutics (Nasdaq: SRPT) unveiled mixed results late Monday for its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in patients with Duchenne muscular dystrophy between the ages of four through seven years. The stock was halted in late trading.

In the study, Elevidys-treated patients improved 2.6 points on their North Star Ambulatory Assessment (NSAA) total score 52 weeks after treatment compared to 1.9 points in placebo-treated patients.

However, the trial missed the primary North Star Ambulatory Assessment/NSAA endpoint, with a treatment difference of 0.65-points (p=0.2441).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology